Adenocarcinoma of the Prostate Clinical Trial
Official title:
A Randomized Phase II Study Of BMS 247550 Or Mitoxantrone And Prednisone In Patients With Taxane Resistant Hormone Refractory Prostate Cancer
Verified date | February 2017 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized phase II trial is studying ixabepilone to see how well it works compared to mitoxantrone and prednisone in treating patients with metastatic prostate cancer that has not responded to paclitaxel, docetaxel, or hormone therapy. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Ixabepilone may reduce resistance to the drugs and allow the tumor cells to be killed. It is not yet known which chemotherapy regimen is more effective in treating metastatic prostate cancer
Status | Completed |
Enrollment | 80 |
Est. completion date | |
Est. primary completion date | October 1, 2007 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed adenocarcinoma of the prostate - Metastatic disease (positive bone scan or measurable disease) - Progressive hormone-refractory disease - Based on 1 of the following: - Transaxial imaging - Rise in prostate-specific antigen (PSA) - Radionuclide bone scan - Must have undergone primary hormonal treatment (e.g., orchiectomy or gonadotropin-releasing hormone analog with or without an antiandrogen) and demonstrated disease progression after antiandrogen discontinuation as defined below: - Two consecutive rising PSA values, obtained at least 2 weeks apart, or documented osseous or soft tissue progression - For patients receiving flutamide, at least 1 PSA value must be obtained at least 4 weeks after flutamide discontinuation - For patients receiving bicalutamide or nilutamide, at least 1 PSA value must be obtained at least 6 weeks after antiandrogen discontinuation - Ineligible if sole manifestation of progression is an increase in disease-related symptoms - Meets 1 of the following criteria: - Measurable disease and an elevated PSA - Nonmeasurable disease and an elevated PSA, as follows: - Positive bone scan - PSA level at least 5 ng/mL, with increases on at least 2 successive occasions at least 2 weeks apart - New metastatic lesions by radionuclide bone scan - Must have received at least 2 courses of paclitaxel- or docetaxel-based therapy, with disease progression documented during therapy or no more than 60 days after cessation of therapy* - Testosterone < 50 ng/dL - No known active brain metastases - Performance status - ECOG 0-2 - At least 12 weeks - Granulocyte count = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Bilirubin < 1.5 times upper limit of normal (ULN) - AST and ALT < 3 times ULN - Creatinine = 1.5 times ULN - Creatinine clearance > 40 mL/min - Ejection fraction = lower limit of normal by MUGA or echocardiogram - No myocardial infarction within the past 6 months - No significant cardiovascular disease - No New York Heart Association class III or IV congestive heart failure - No active angina pectoris - Fertile patients must use effective contraception before, during, and for 3 months after study therapy - No prior hypersensitivity reaction to agents containing Cremophor®EL - No serious infection - No nonmalignant medical illnesses that are uncontrolled or whose control would be jeopardized by complications of study therapy - No psychiatric illness or social situation that would preclude study compliance - No motor or sensory neuropathy grade 2 or greater - No "currently active" second malignancy except nonmelanoma skin cancer - Patients are not considered to have a "currently active" malignancy provided they have completed therapy and are considered to have less than a 30% risk of relapse - No concurrent prophylactic colony-stimulating factors for myelosuppression - See Disease Characteristics - No more than 1 prior chemotherapy regimen - No prior mitoxantrone or epothilone - No other concurrent chemotherapy - See Disease Characteristics - At least 4 weeks since prior antiandrogens (e.g., flutamide) (6 weeks for bicalutamide or nilutamide) - Patients must continue primary androgen deprivation therapy with luteinizing hormone-releasing hormone agonist during study if prior orchiectomy was not performed - At least 4 weeks since prior systemic (including oral) corticosteroids except corticosteroids as part of first-line chemotherapy tapered off over 10-14 days prior to study entry - At least 4 weeks since any prior hormonal therapy, including megestrol or finasteride - No other concurrent systemic steroids - At least 4 weeks since prior radiotherapy - More than 8 weeks since prior radiopharmaceuticals (e.g., strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium) - No concurrent radiotherapy - See Disease Characteristics - At least 4 weeks since prior herbal products known to decrease PSA levels (e.g., Saw Palmetto or PC-SPES) - More than 4 weeks since other prior antiprostate cancer therapy - More than 4 weeks since prior systemic therapies for prostate cancer - No other concurrent investigational agents |
Country | Name | City | State |
---|---|---|---|
United States | UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response to the randomized treatment as determined by > 50% PSA response as measured by RECIST criteria | The frequency of response with 95% confidence limits for a binomial outcome will be calculated. | Up to 3 months | |
Secondary | Frequency of any toxicity by grade | Up to 3 months | ||
Secondary | Response duration | Will be estimated using the Kaplan-Meier product limit method. | From the date PR or CR is first determined until the first evidence of progressive disease, assessed up to 3 months | |
Secondary | Time to progressive disease | Will be estimated using the Kaplan-Meier product limit method. | From the date protocol therapy is started until the first evidence of progressive disease, assessed up to 3 months | |
Secondary | Frequency of response to third-line (crossover) therapy | Estimates of response to third line treatment along with 95% confidence intervals will be calculated. | Up to 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02217709 -
Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer
|
Phase 2 | |
Completed |
NCT03077659 -
Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03624660 -
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
|
N/A | |
Completed |
NCT01054079 -
Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer
|
Phase 2 | |
Terminated |
NCT00512668 -
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
|
Phase 1 | |
Completed |
NCT00087139 -
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
|
Phase 2 | |
Completed |
NCT00182052 -
Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03511196 -
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
|
Early Phase 1 | |
Active, not recruiting |
NCT01655836 -
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
|
Phase 1 | |
Terminated |
NCT03535675 -
Muscadine Plus (MPX) In Men With Prostate Cancer
|
Phase 3 | |
Terminated |
NCT01866423 -
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT02234921 -
Pilot Study of DRibble Vaccine for Prostate Cancer Patients
|
Phase 1 | |
Completed |
NCT01468532 -
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03686683 -
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03689699 -
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04694924 -
Prospective Prostate Cancer and Patient-reported Outcomes Registry
|
||
Active, not recruiting |
NCT04909294 -
Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma
|
N/A | |
Completed |
NCT02225925 -
Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound
|
N/A | |
Completed |
NCT01949519 -
Docetaxel and Lycopene in Metastatic Prostate Cancer
|
Phase 1 | |
Completed |
NCT01433913 -
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
|
Phase 2 |